Novo Nordisk Aktie
59,12
EUR
-1,76
EUR
-2,89
%
59,42
EUR
-0,58
EUR
-0,97
%
Werbung
Novo Nordisk Aktie Analyse
14.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
07.05.20 | Novo Nordisk overweight | Barclays Capital | |
07.05.20 | Novo Nordisk Outperform | Credit Suisse Group | |
06.05.20 | Novo Nordisk buy | UBS AG | |
06.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
06.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
Werbung
|
|||
29.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
17.04.20 | Novo Nordisk buy | UBS AG | |
15.04.20 | Novo Nordisk buy | UBS AG | |
15.04.20 | Novo Nordisk Outperform | Bernstein Research | |
14.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
09.04.20 | Novo Nordisk overweight | Barclays Capital | |
07.04.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
24.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
23.03.20 | Novo Nordisk buy | UBS AG | |
18.03.20 | Novo Nordisk Outperform | Bernstein Research | |
17.03.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
17.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
17.03.20 | Novo Nordisk overweight | Barclays Capital | |
02.03.20 | Novo Nordisk overweight | Barclays Capital | |
25.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
06.02.20 | Novo Nordisk Outperform | Credit Suisse Group | |
06.02.20 | Novo Nordisk overweight | Barclays Capital | |
06.02.20 | Novo Nordisk Outperform | Bernstein Research | |
06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
06.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
05.02.20 | Novo Nordisk overweight | Barclays Capital | |
05.02.20 | Novo Nordisk Outperform | Bernstein Research | |
05.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
31.01.20 | Novo Nordisk overweight | Barclays Capital | |
29.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
20.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
17.01.20 | Novo Nordisk overweight | Barclays Capital | |
17.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
16.01.20 | Novo Nordisk overweight | Barclays Capital | |
16.01.20 | Novo Nordisk Outperform | Credit Suisse Group | |
06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
06.01.20 | Novo Nordisk kaufen | Bernstein Research | |
21.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
21.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
18.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
18.11.19 | Novo Nordisk overweight | Barclays Capital | |
06.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
04.11.19 | Novo Nordisk Outperform | Credit Suisse Group | |
04.11.19 | Novo Nordisk Outperform | Bernstein Research | |
04.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
01.11.19 | Novo Nordisk buy | UBS AG |
Werbung
Werbung